부산대학교 도서관

Checkpoint inhibitors (CPIs) are immunotherapy drugs used to treat cancer by boosting the immune system, but they can cause side effects, including liver damage. This document provides an overview of CPI-induced liver injury and how to manage it. Combination therapy with certain drugs carries a higher risk of adverse events. The document also discusses risk factors, diagnosis, and treatment guidelines for checkpoint inhibitor hepatitis (CPI-H). Further research is needed to identify definitive risk factors and refine treatment guidelines. The article emphasizes the importance of biomarkers and diagnostic tools to personalize treatment strategies. [Extracted from the article]